Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.

Gooding S, Lau IJ, Sheikh M, Roberts P, Wong J, Dickens E, Bullement A, Elvidge J, Lee D, Ramasamy K.

PLoS One. 2015 Sep 14;10(9):e0136207. doi: 10.1371/journal.pone.0136207. eCollection 2015.

2.

A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.

Blommestein HM, Verelst SG, de Groot S, Huijgens PC, Sonneveld P, Uyl-de Groot CA.

Eur J Haematol. 2016 Feb;96(2):198-208. doi: 10.1111/ejh.12571. Epub 2015 May 7.

PMID:
25892333
3.

Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.

Borg S, Nahi H, Hansson M, Lee D, Elvidge J, Persson U.

Acta Oncol. 2016 May;55(5):554-60. doi: 10.3109/0284186X.2015.1096021. Epub 2015 Nov 17.

PMID:
27123742
4.

Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.

Möller J, Nicklasson L, Murthy A.

J Med Econ. 2011;14(6):690-7. doi: 10.3111/13696998.2011.611841. Epub 2011 Sep 5.

PMID:
21892856
5.

Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.

Armoiry X, Fagnani F, Benboubker L, Facon T, Fermand JP, Hulin C, Moreau P, Aulagner G.

J Clin Pharm Ther. 2011 Feb;36(1):19-26. doi: 10.1111/j.1365-2710.2009.01153.x.

PMID:
21198717
6.

Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.

Arikian SR, Milentijevic D, Binder G, Gibson CJ, Hu XH, Nagarwala Y, Hussein M, Corvino FA, Surinach A, Usmani SZ.

Curr Med Res Opin. 2015 Jun;31(6):1105-15. doi: 10.1185/03007995.2015.1031732. Epub 2015 Apr 17.

PMID:
25785551
7.

Spotlight on lenalidomide in relapsed or refractory multiple myeloma.

Scott LJ, Lyseng-Williamson KA.

BioDrugs. 2011 Oct 1;25(5):333-7. doi: 10.2165/11207120-000000000-00000. Review.

PMID:
21942918
9.

Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.

Gaultney JG, Franken MG, Tan SS, Redekop WK, Huijgens PC, Sonneveld P, Uyl-de Groot CA.

J Clin Pharm Ther. 2013 Feb;38(1):41-7. doi: 10.1111/jcpt.12020. Epub 2012 Nov 6.

PMID:
23126374
10.

Lenalidomide for the treatment of relapsed multiple myeloma.

Gajraj E, Chung H, Boysen M, Barnett DB, Longson C.

Lancet Oncol. 2009 Jul;10(7):647-8. No abstract available.

PMID:
19585686
11.

Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.

Gonzalez-McQuire S, Yong K, Leleu H, Mennini FS, Flinois A, Gazzola C, Schoen P, Campioni M, DeCosta L, Fink L.

J Med Econ. 2018 May;21(5):450-467. doi: 10.1080/13696998.2017.1421546. Epub 2018 Jan 10.

PMID:
29278014
12.

Total cost comparison in relapsed/refractory multiple myeloma.

Durie B, Binder G, Pashos C, Khan Z, Hussein M, Borrello I.

J Med Econ. 2013;16(5):614-22. doi: 10.3111/13696998.2012.760159. Epub 2013 Mar 19.

13.

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.

Lau IJ, Smith D, Aitchison R, Blesing N, Roberts P, Peniket A, Yong K, Rabin N, Ramasamy K.

Ann Hematol. 2015 Apr;94(4):643-9. doi: 10.1007/s00277-014-2238-2. Epub 2014 Oct 28.

PMID:
25345871
14.

Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.

Majer I, van de Wetering G, Polanyi Z, Krishna A, Gray E, Roy A.

Appl Health Econ Health Policy. 2017 Feb;15(1):45-55. doi: 10.1007/s40258-016-0271-0.

PMID:
27550239
15.
16.

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.

Pelligra CG, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, Ailawadhi S.

Clin Ther. 2017 Oct;39(10):1986-2005.e5. doi: 10.1016/j.clinthera.2017.08.010. Epub 2017 Sep 28.

17.

Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?

Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, Uyl-de Groot CA.

Value Health. 2014 Mar;17(2):245-53. doi: 10.1016/j.jval.2013.12.009.

18.

Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.

Olszewski AJ, Dusetzina SB, Eaton CB, Davidoff AJ, Trivedi AN.

J Clin Oncol. 2017 Oct 10;35(29):3306-3314. doi: 10.1200/JCO.2017.72.2447. Epub 2017 May 25.

19.

Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?

Aguiar PM, Lima TM, Storpirtis S.

J Clin Pharm Ther. 2016 Apr;41(2):189-97. doi: 10.1111/jcpt.12384. Epub 2016 Mar 23. Review.

PMID:
27009796
20.

Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience.

Zhou X, Xia J, Mao J, Cheng F, Qian X, Guo H.

Hematology. 2016 Jun;21(5):280-6. doi: 10.1080/10245332.2015.1122259. Epub 2016 Mar 1.

PMID:
26900623

Supplemental Content

Support Center